Ensysce Biosciences, Inc. Income Statement
ENSC|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Ensysce Biosciences, Inc. reported $5M in revenue and $8M in net loss for FY2025. Revenue has grown at a 13.8% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $5.2M | $2.2M | $2.5M | $3.5M |
| SG&A Expense | $4.7M | $5.4M | $6.9M | $18.7M |
| R&D Expense | $7.2M | $7.6M | $19.8M | $4.7M |
| Operating Income | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Interest Expense | $8.8K | $14.7K | $109.5K | $1.3M |
| Net Income | -$8.0M | -$10.6M | -$24.2M | -$29.1M |
| EPS (Basic) | -$11.45 | -$70.40 | -$139.42 | -$29.64 |
| EPS (Diluted) | -$11.45 | -$70.40 | -$139.42 | - |
| Shares Outstanding | 1.4M | 209.7K | 534.5K | 311.0K |
| Operating Margin | -129.2% | -480.5% | -959.9% | -562.7% |
| Profit Margin | -153.3% | -476.4% | -959.3% | -825.4% |